HIV-I Nef inhibitors: a novel class of HIV-specific immune adjuvants in support of a cure
Abstract The success of many current vaccines relies on a formulation that incorporates an immune activating adjuvant. This will hold true for the design of a successful therapeutic HIV vaccine targeted at controlling reactivated virus following cessation of combined antiretroviral therapy (cART). T...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2017-09-01
|
| Series: | AIDS Research and Therapy |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12981-017-0175-6 |